Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00498628|
Recruitment Status : Completed
First Posted : July 10, 2007
Results First Posted : May 30, 2012
Last Update Posted : April 25, 2018
|Condition or disease||Intervention/treatment||Phase|
|Alcoholism Alcohol Abuse||Drug: Quetiapine fumarate Other: Placebo||Phase 2|
This study will investigate quetiapine fumarate XR (SEROQUEL XR®), a dibenzothiazepine derivative, as a potential medication for treating alcohol dependence. The immediate release form of quetiapine fumarate, SEROQUEL XR®, is approved by the FDA for treatment of schizophrenia and acute manic episodes associated with bipolar disorder. The extended release formulation (SEROQUEL XR®) is also approved by the FDA and is undergoing clinical investigation for the treatment of major depressive disorders, schizophrenia, generalized anxiety disorder, and alcohol dependence.
Treatment with other atypical antipsychotics such as clozapine and olanzapine has resulted in decreases in alcohol use in alcohol dependent patients with and without comorbid psychiatric diagnoses. Quetiapine, like clozapine, appears to have efficacy in reducing drug and alcohol use among alcoholics and drug dependent patients with co-morbid psychiatric illness.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||224 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Quetiapine Fumarate Extended Release for the Treatment of Alcohol Dependence in Very Heavy Drinkers.|
|Study Start Date :||December 2007|
|Actual Primary Completion Date :||August 2009|
|Actual Study Completion Date :||March 2010|
Quetiapine fumarate plus medical management
Drug: Quetiapine fumarate
Quetiapine fumarate- taken daily, for 12 weeks
Other Name: SEROQUEL XR
Placebo Comparator: 2
Medical management plus placebo comparator
- Percent Heavy Drinking Days [ Time Frame: Weeks 3 - 11 ]A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period.
- Percent Days Abstinent [ Time Frame: 3-11 ]Percentage of days abstinent (PDA) between Study Days 15 and 77
- Drinks Per Drinking Day [ Time Frame: 3-11 ]
- Drinks Per Day [ Time Frame: 3-11 ]
- Percent Very Heavy Drinking Day [ Time Frame: 3-11 ]
- Percent Subjects Abstinent [ Time Frame: 3-11 ]
- Percent Subjects With no Heavy Drinking Day [ Time Frame: 3-11 ]
- Drinking Consequences Score [ Time Frame: Weeks 6 and 12 ]Drinkers Inventory of Consequences (DrInC) - Alcohol-related problems are determined using the DrInC (Miller et al., 1995). The DrInC is a self-administered 50-item questionnaire designed to measure adverse consequences of alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. Each scale provides a lifetime and past 3-month measure of adverse consequences, and scales can be combined to assess total adverse consequences. At baseline the DrInC-2R will be used to assess the 90-day period prior to baseline. For weeks 6 and 12, the DrInC-2R will be used, but will be modified to assess alcohol-related problems over the previous 6-week period.
- Penn Alcohol Craving Score (PACS_ [ Time Frame: Week 4, 6, 8, 10, 12 ]The Penn Alcohol Craving Scale (PACS) is a five-item, self-report measure that includes questions about the frequency, intensity, and duration of craving, the ability to resist drinking, and asks for an overall rating of craving for alcohol for the previous week (Flannery et al., 1999). Based on clinical study results, the PACS have been shown to be a reliable and valid measure of alcohol craving and can predict subjects at risk for subsequent relapse.
- Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: Week 4, 6, 8, 10, and 12 ]The MADRS is an observer rating scale that has proven to be an efficient and practical measure of depression (Montgomery and Asberg, 1979). The scale was constructed to be sensitive to changes in treatment effects. Its capacity to differentiate between responders and non-responders to antidepressant treatment has been shown to be comparable to the Hamilton Rating Scale for Depression, another established measure of depressive symptomatology, but the MADRS has greater sensitivity to change during the course of a depressive phase. It has exhibited high inter-rater reliability and appears to be oriented more towards psychic as opposed to somatic aspects of depression. The MADRS is a 10-item checklist where items are rated on a scale of 0 to 6 with anchors at 2-point intervals. Scores range from 0 to 60.
- Hamilton Anxiety Scale (HAM-A) [ Time Frame: Weeks 4, 6, 8, 10 and 12 ]The Hamilton Anxiety Scale consists of 14 items, each defined by a series of symptoms. Similar to the HAM-D, each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe). (Guy, 1976).
- Sleep Quality Score [ Time Frame: Weeks 4, 8 and 12 ]The Pittsburgh Sleep Quality Index is a 19-item questionnaire with seven sub scales (subjective sleep quality, sleep latency, sleep duration, habitual sleep disturbances, use of sleep medication and day time dysfunction) (Buysse et al., 1989). Each sub-scale is rated from 0-3 with the higher scores reflecting more severe sleep complaints. The addition of all the scores permits an analysis of the subject's overall sleep experience in the past 30 days. The lower the overall score, the better the person sleeps. The tool has an adequate internal reliability, validity and consistency for clinical and community samples of the various populations.
- Quality of Life SF - 12 [ Time Frame: Week 12 ]The SF-12 will be used to assess overall health status. The SF-12 is a 12-item questionnaire developed in 1994 as a shorter alternative to the SF-36 to reproduce the physical and mental health summary measures with at least 90% accuracy and allows for calculation of the physical and mental component summary scores.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00498628
|United States, Massachusetts|
|Boston University School of Medicine, Psychiatry Clinical Studies Unit|
|Boston, Massachusetts, United States, 02118|
|United States, New Hampshire|
|Dartmouth Medical School, Dept. of Psychiatry|
|Lebanon, New Hampshire, United States, 03755|
|United States, Pennsylvania|
|University of Pennsylvania, Treatment Research Center|
|Philadelphia, Pennsylvania, United States, 19104|
|United States, Rhode Island|
|Brown University Center for Alcohol and Addiction Studies|
|Providence, Rhode Island, United States, 12906|
|United States, Vermont|
|White River Junction VA Medical Center|
|White River Junction, Vermont, United States, 05009|
|United States, Virginia|
|University of Virginia, Dept. of Psychiatric Medicine|
|Charlottesville, Virginia, United States, 22908|
|University of Virginia|
|Richmond, Virginia, United States, 23294|
|Study Director:||Raye Z. Litten, PhD||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|
|Principal Investigator:||Margaret E. Mattson, PhD||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|
|Principal Investigator:||Joanne Fertig, PhD||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|